Dexcel Pharma Technologies Ltd. - Apr 22, 2022 Form 4 Insider Report for Roivant Sciences Ltd. (ROIV)

Role
10%+ Owner
Signature
/s/ Dexcel Pharma Technologies Ltd. by Dan Oren, Executive Chairman
Stock symbol
ROIV
Transactions as of
Apr 22, 2022
Transactions value $
$154,954
Form type
4
Date filed
4/26/2022, 06:48 AM
Previous filing
Oct 1, 2021
Next filing
Nov 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ROIV Common Shares Purchase $121K +31.7K +0.03% $3.83 98.8M Apr 22, 2022 Direct F1, F2, F4
transaction ROIV Common Shares Purchase $33.6K +8.6K +0.01% $3.91 98.8M Apr 25, 2022 Direct F1, F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Dexcel Pharma Technologies Ltd. ("Dexcel") is the direct beneficial holder of 684,130 common shares. Dexxon Holding Ltd. ("Dexxon") is the direct beneficial holder of 98,165,313 common shares. Dan Oren is the Executive Chairman of Dexcel and the sole director of Dexxon and is ultimately the sole shareholder of each entity.
F2 The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.685 to $3.88.
F3 The price reported in Column 4 is the weighted average price. The common shares were purchased in multiple transactions at prices ranging from $3.825 to $3.99.
F4 The Reporting Persons hereby undertake to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transactions were effected.